ESTRADIOL AND NORETHINDRONE ACETATE

Post-LOE

estradiol and norethindrone acetate

Aurobindo Pharma

ANDAORALTABLET

Approved

Apr 2019

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

ESTRADIOL AND NORETHINDRONE ACETATE (estradiol and norethindrone acetate) by Aurobindo Pharma is estrogen receptor agonists [moa]. Approved for osteoporosis, osteoporosis. First approved in 2019.

Drug data last refreshed 23h ago

Mechanism of Action

Estrogen Receptor Agonists

Pharmacologic Class:

Estrogen

Indications (1)

Osteoporosis

Company

Worked on ESTRADIOL AND NORETHINDRONE ACETATE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.